Proposed Data Collection Submitted for Public Comment and Recommendations, 72238-72239 [2021-27599]
Download as PDF
<![CDATA[
72238
Federal Register / Vol. 86, No. 242 / Tuesday, December 21, 2021 / Notices
Dated at Washington, DC, on December 15,
2021.
James P. Sheesley,
Assistant Executive Secretary.
[FR Doc. 2021–27525 Filed 12–20–21; 8:45 am]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
jspears on DSK121TN23PROD with NOTICES1
A. Federal Reserve Bank of Dallas
(Karen Smith, Director, Applications)
2200 North Pearl Street, Dallas, Texas
75201–2272:
1. Brittany Broke Lane, Jonestown,
Texas; by retaining voting shares of
Shelby Bancshares, Inc., and thereby
indirectly retaining voting shares of
Shelby Savings Bank, SSB, both of
Center, Texas.
Board of Governors of the Federal Reserve
System, December 16, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–27604 Filed 12–20–21; 8:45 am]
BILLING CODE P
Jkt 256001
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington DC 20551–0001, not later
than January 5, 2022.
18:02 Dec 20, 2021
Centers for Disease Control and
Prevention
[60Day-22–22BG; Docket No. CDC–2021–
0131]
BILLING CODE 6714–01–P
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comments on a
proposed information collection project
titled Characteristics of Patients with
Environmentally-derived Triazoleresistant Aspergillus fumigatus. This
case report form collects information on
demographics, underlying conditions,
treatments, and outcomes of patients
with triazole-resistant A. fumigatus to
inform clinical and public health
practice.
SUMMARY:
CDC must receive written
comments on or before February 22,
2022.
DATES:
You may submit comments,
identified by Docket No. CDC–2021–
0131 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8 Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
ADDRESSES:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Prevention, 1600 Clifton Road, NE, MS
H21–8, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Patients with
Environmentally-derived Triazoleresistant Aspergillus fumigatus—New—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The environmental mold Aspergillus
fumigatus (A. fumigatus) is the primary
cause of invasive aspergillosis and is
associated with ∼50% mortality in highrisk patients, including stem cell and
organ transplant recipients. The use of
triazole antifungals has greatly
improved survival. However, triazoleresistant A. fumigatus infections are
E:\FR\FM\21DEN1.SGM
21DEN1
72239
Federal Register / Vol. 86, No. 242 / Tuesday, December 21, 2021 / Notices
increasingly reported worldwide and
are associated with increased mortality
and treatment failure. Of particular
concern are resistant A. fumigatus
isolates carrying the TR34/L98H and
TR46/Y121F genetic resistance markers,
which are associated with
environmental triazole fungicide use
rather than previous patient exposure to
antifungals. Infections with these
triazole-resistant strains have become
common among patients with A.
fumigatus infections in Europe, Asia,
and South America, and have been
characterized epidemiologically.
However, U.S. reports of isolates
carrying TR34/L98H or TR46/Y121F
markers are limited, and detailed
epidemiologic data are critical to inform
public health response.
departments and contains an optional
supplement at the end involving a brief
interview (including data on
occupational and environmental
exposures) of a patient or their
representative. The findings would be
used to describe the risk factors, clinical
features, and outcomes for patients with
triazole-resistance Aspergillus
fumigatus. U.S. data on triazoleresistant Aspergillus fumigatus are
lacking, although this problem
constitutes a major public health threat.
CDC requests OMB approval for an
estimated 8 annual burden hours
annually for collection from 15
respondents. There are no costs to
respondents other than their time.
Through the Antibiotic Resistance
Laboratory Network (ARLN), CDC is
already receiving A. fumigatus isolates
from laboratories across the nation.
These isolates undergo testing for
triazole resistance (defined using
minimum inhibitory concentrations or
epidemiologic cutoff values set forth by
Clinical and Laboratory Standards
Institute). For patients involving
triazole-resistant isolates, we plan to use
a standardized case report form (CRF) to
collect public health surveillance data
regarding demographics (e.g., age, sex,
race/ethnicity, country of residence),
underlying medical conditions,
treatments, and outcomes (e.g., vital
status at 30 days for initial positive
specimen). The CRF would be filled out
voluntarily by state and local health
ESTIMATED ANNUALIZED BURDEN HOURS
Type of
respondents
State and Local Health
Department.
Total ........................
Average
burden per
response
(in hours)
Total Burden
(in hours)
15
15
30/60
8
..............................................................................
........................
........................
........................
8
[FR Doc. 2021–27599 Filed 12–20–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
CDC must receive written
comments on or before February 22,
2022.
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
18:02 Dec 20, 2021
Jkt 256001
You may submit comments,
identified by Docket No. CDC–2021–
0130 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
ADDRESSES:
Proposed Data Collection Submitted
for Public Comment and
Recommendations
SUMMARY:
This notice invites comment on a
proposed information collection project
titled 2022 Million Hearts®
Hypertension Control Champions
Challenge. This program will be used to
identify clinicians, clinical practices,
and health systems that have
exceptional rates of hypertension
control and recognize them as 2022
Million Hearts® Hypertension Control
Champions.
DATES:
[60-Day–22–0976; Docket No. CDC–2021–
0130]
jspears on DSK121TN23PROD with NOTICES1
Number of
responses per
respondent
Characteristics of Patients with Environmentallyderived Triazole-resistant Aspergillus
fumigatus.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
VerDate Sep<11>2014
Number of
respondents
Form name
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329; phone:
404–639–7118; Email: omb@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
SUPPLEMENTARY INFORMATION:
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 86, Number 242 (Tuesday, December 21, 2021)]
[Notices]
[Pages 72238-72239]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27599]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-22-22BG; Docket No. CDC-2021-0131]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction Act of 1995. This notice invites comments on a proposed
information collection project titled Characteristics of Patients with
Environmentally-derived Triazole-resistant Aspergillus fumigatus. This
case report form collects information on demographics, underlying
conditions, treatments, and outcomes of patients with triazole-
resistant A. fumigatus to inform clinical and public health practice.
DATES: CDC must receive written comments on or before February 22,
2022.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-
0131 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8 Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road, NE, MS H21-8, Atlanta, Georgia 30329; phone: 404-639-7570; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
Characteristics of Patients with Environmentally-derived Triazole-
resistant Aspergillus fumigatus--New--National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The environmental mold Aspergillus fumigatus (A. fumigatus) is the
primary cause of invasive aspergillosis and is associated with ~50%
mortality in high-risk patients, including stem cell and organ
transplant recipients. The use of triazole antifungals has greatly
improved survival. However, triazole-resistant A. fumigatus infections
are
[[Page 72239]]
increasingly reported worldwide and are associated with increased
mortality and treatment failure. Of particular concern are resistant A.
fumigatus isolates carrying the TR34/L98H and TR46/Y121F genetic
resistance markers, which are associated with environmental triazole
fungicide use rather than previous patient exposure to antifungals.
Infections with these triazole-resistant strains have become common
among patients with A. fumigatus infections in Europe, Asia, and South
America, and have been characterized epidemiologically. However, U.S.
reports of isolates carrying TR34/L98H or TR46/Y121F markers are
limited, and detailed epidemiologic data are critical to inform public
health response.
Through the Antibiotic Resistance Laboratory Network (ARLN), CDC is
already receiving A. fumigatus isolates from laboratories across the
nation. These isolates undergo testing for triazole resistance (defined
using minimum inhibitory concentrations or epidemiologic cutoff values
set forth by Clinical and Laboratory Standards Institute). For patients
involving triazole-resistant isolates, we plan to use a standardized
case report form (CRF) to collect public health surveillance data
regarding demographics (e.g., age, sex, race/ethnicity, country of
residence), underlying medical conditions, treatments, and outcomes
(e.g., vital status at 30 days for initial positive specimen). The CRF
would be filled out voluntarily by state and local health departments
and contains an optional supplement at the end involving a brief
interview (including data on occupational and environmental exposures)
of a patient or their representative. The findings would be used to
describe the risk factors, clinical features, and outcomes for patients
with triazole-resistance Aspergillus fumigatus. U.S. data on triazole-
resistant Aspergillus fumigatus are lacking, although this problem
constitutes a major public health threat.
CDC requests OMB approval for an estimated 8 annual burden hours
annually for collection from 15 respondents. There are no costs to
respondents other than their time.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total Burden
respondents respondent (in hours) (in hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
State and Local Health Department.............. Characteristics of Patients with 15 15 30/60 8
Environmentally-derived Triazole-
resistant Aspergillus fumigatus.
---------------------------------------------------------------
Total...................................... ....................................... .............. .............. .............. 8
--------------------------------------------------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-27599 Filed 12-20-21; 8:45 am]
BILLING CODE 4163-18-P
